Sexual dysfunction in people treated with long‐acting injectable antipsychotics in monotherapy or polypharmacy: a naturalistic study

IntroductionAripiprazole depot is an atypical antipshycotic used to treat positive and negative symptoms of psychosis or acute mania.AimDescribe the reason why psychiatrists switch the current antipsychotic treatment on to aripiprazol depot, its tolerability and the reasons to stop aripiprazol depot treatment.MethodsDescriptive analysis based on a sample of 37 patients, aged 18–65 years, treated during one year with antipsychotics at two community mental health units.ResultsSwitching on to aripiprazole depot principal reasons: promote adherence (25%), persistence of symptoms (25%) and high levels of prolactin or sexual dysfunction (16.66%):– side effects of aripiprazole depot: insomnia (11.11%), inquietude (8.33%), sexual dysfunction (2.77%) and hypertensive crisis during administration (2.77%);– 83.33% of the patients are still taking it after one year. The most common reasons to stop or change it were the presence of secondaries (11.11%) and clinical exacerbation (5.55%).ConclusionsAripiprazole depot is well tolerated (even better than other antipsychotics). Common side effects are not severe and appear in a small percent of patients.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

P.083 Sexual dysfunction in young schizophrenic patients: an indirect comparison between three long‐acting antipsychotics

European Neuropsychopharmacology ◽

10.1016/j.euroneuro.2019.09.141 ◽

2019 ◽

Vol 29 ◽

pp. S75-S76

Author(s):

S.L. Romero Guillena ◽

F. Gotor Sánchez-Luengo ◽

B.O. Plasencia Garcia de Diego

Keyword(s):

Sexual Dysfunction ◽

Indirect Comparison ◽

Schizophrenic Patients ◽

Long Acting

Download Full-text

Aripiprazole long-acting injection: a naturalistic study in a community setting

10.26226/morressier.5971be85d462b80290b52492 ◽

2017 ◽

Author(s):

Chiara Vannini

Keyword(s):

Community Setting ◽

Naturalistic Study ◽

Long Acting

Download Full-text

Sexual dysfunction in men treated with depot antipsychotic drugs: a pilot study

Sexual Health ◽

10.1071/sh07012 ◽

2007 ◽

Vol 4 (4) ◽

pp. 269 ◽

Cited By ~ 2

Author(s):

David Plevin ◽

Cherrie Galletly ◽

Penny Roughan

Keyword(s):

Sexual Dysfunction ◽

Sexual Function ◽

Antipsychotic Drugs ◽

Elevated Serum ◽

Serum Testosterone ◽

Chronic Schizophrenia ◽

Structured Interview ◽

Drug Dose ◽

Serum Prolactin ◽

Long Acting

Background: Sexual dysfunction is common, but often under-recognised, in people with schizophrenia. Many antipsychotic drugs are known to cause prolactin elevation, and it is often assumed that sexual dysfunction is a consequence of prolactin elevation. We investigated the relationship between sexual function and serum concentrations of prolactin and testosterone in men receiving regular long-acting depot injections of antipsychotic medication. Methods: Twenty-two men attending a community depot clinic participated. A structured interview was used to collect information about sexual function, and serum prolactin and testosterone concentrations were measured. Results: Sexual dysfunction was common, with 73% of men reporting problems in at least one area of sexual function. Six men had elevated serum prolactin and one had reduced serum testosterone. Antipsychotic drug dose was positively correlated with serum prolactin and negatively correlated with serum testosterone, but there was no association between serum prolactin or testosterone concentrations and any measure of sexual dysfunction. Conclusion: Sexual dysfunction is a major problem for men living with chronic schizophrenia, but our results suggest that it is not directly attributable to elevated prolactin or reduced testosterone concentrations.

Download Full-text

T167. QUALITATIVE DIFFERENCES IN LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS AMONG SCHIZOPHRENIA PATIENTS

Schizophrenia Bulletin ◽

10.1093/schbul/sbaa029.727 ◽

2020 ◽

Vol 46 (Supplement_1) ◽

pp. S295-S295

Author(s):

Valeria Karakasi ◽

Pavlos Pavlidis ◽

Aikaterini Vlachaki

Keyword(s):

Sexual Dysfunction ◽

Adverse Effects ◽

Psychiatric Treatment ◽

Time Frame ◽

Cardiovascular Complications ◽

Schizophrenia Spectrum ◽

Individualized Approach ◽

Long Acting ◽

Haloperidol Treatment

Abstract Background The purpose of this presentation is to investigate qualitative differences associated with treatment of Schizophrenia spectrum disorder patients with long acting injectable (LAI) antipsychotics, including adverse effects and efficacy. Methods Literature around LAI antipsychotics and their comparative data was reviewed and evaluated via all electronic databases up to December 2018. Results Metabolic, hepatic and cardiovascular complications in olanzapine treatment have been the major concern in most studies, despite the effectiveness of the medication, as coronary heart disease is strongly associated with a decrease in the life expectancy of schizophrenia patients (coupled with higher levels of smoking and malnutrition). Treatment with risperidone was associated with a worsening of depressive affect and suicidal ideation (except prolactin-related and extrapyramidal adverse effects), as well as sexual dysfunction. Hyperprolactinemia, extrapyramidal / neurological symptoms, and sexual dysfunction were the major problems with haloperidol treatment despite a good efficacy profile with respect to positive symptoms of schizophrenia. Sporadic effectiveness, agitation and, to a lesser extent, weight gain were some of the concerns in palimperidone treatment. Aripiprazole treatment was associated with a comparatively milder and in the long term more preferable adverse effect profile, while exhibiting similarly high levels of efficacy with olanzapine in controlling schizophrenia symptoms, but with a reported relatively higher rate in treatment discontinuation (drop-outs) in comparison to olanzapine and haloperidol in case of schizophrenia (in contrast to schizoaffective disorder in which high levels of both compliance and effectiveness are exhibited). Discussion The need for an individualized approach in psychiatric treatment highlighted so that the needs of each patient be taken into account by the therapist in choosing the optimal treatment within a given time frame.

Download Full-text